- Disclosing Financial Conflicts f Interest To Research …
- Nursing student hopes her research makes life better for sickle …
- Duke to begin $700M hospital expansion
- Dominion Clinical Research offers different approach to mental …
- Disclosure of Financial Relationships to Participants in Clinical …
- Delays in vaccine trials inject flu questions

Disclosing Financial Conflicts f Interest To Research …
Science Daily (press release)
senior author of a paper published in the August 27th issue of The New England Journal of Medicine and the deputy director for medicine at the Berman Institute of Bioethics at Johns Hopkins. The paper drew on five years of research from the Conflict of Interest Notification Study (CINS) a $3 million project led by Sugarman and funded by the National Heart Lung and Blood Institute of the National Institutes of Health. verall CINS gathered information from thousands of patients as well as many clinical trial investigators and those charged with the ethical oversight of research.

Nursing student hopes her research makes life better for sickle …
Indiana State University
Lufkin’s “classrooms” have included some of the most respected names in health care: The Johns Hopkins Hospital in Baltimore Suburban Hospital in Bethesda and most recently the National Institutes of Health where she completed a research fellowship. Her research topic was “what sickle cell anemia patients want their providers and the public to know about living with sickle cell. Pain is the greatest concern for those with sickle cell according to interviews of patients Lufkin conducted during her 10-week fellowship at the Mark. Hatfield Clinical Research Center the nation’s largest hospital devoted entirely to clinical research. “The pain with sickle cell is very similar to post-operative pain or cancer pain. That’s something that many providers who aren’t as familiar with sickle cell may not know” said Lufkin whose study conducted via the center’s Social Work Department was funded by an NIH Intramural Research Training Award Fellowship. Because severe pain can strike at any time many patients seek treatment in hospital emergency rooms often asking for specific highly powerful medications.

Duke to begin $700M hospital expansion
WRAL.com
"This project is all about our patients faculty and staff and our missions of clinical care teaching and pursuing breakthrough research. "The project also will act as an economic driver for the region creating up to 1500 construction jobs and 1000 permanent health care positions officials said. The seven-story 267000-square-foot cancer center will consolidate outpatient cancer services and clinical research from across the campus into a patient-centered multidisciplinary center. It will adjoin to the Morris Cancer Clinic and will include 140 examination rooms 75 infusion stations a pharmacy and an outdoor garden terrace for chemotherapy patients. "Patients in North Carolina and elsewhere will have access to a center of excellence that combines the best in convenient multidisciplinary cancer care along with leading edge approaches to personalized treatment strategies" Dr. William Fulkerson Jr. senior vice president for clinical affairs for Duke Health said in a statement.

Dominion Clinical Research offers different approach to mental …
Midlothian Exchange
Yet Dominion Clinical Research a private outpatient clinical research facility located at 2820 Waterford Lake Dr. 202 is now attempting to lessen the burdens caused by the failing economy. Established in 2000 by board-certified adult and child psychiatrist Dr. Anne Fedyszen and her partner Laurie Burke DCR has continued to provide mental health services for Major Depressive Disorder and other mental health conditions through ongoing clinical research participation and customized private care practice.
Related from Macmedal: CAMH scientist first psychiatrist to win Royal College Medal Award …

Disclosure of Financial Relationships to Participants in Clinical …
New England Journal of Medicine (subscription)
Potential Goals and Challenges of Disclosing Financial Relationships in Clinical Research. Promoting Informed Decision MakingDisclosures to research participants during the informed-consent process are meant to promote autonomous decision making. 789 What exactly constitutes an autonomous decision by the participant is a matter of debate but most experts describe it as a choice made after the person has gained a substantial understanding of the potential risks and benefits of enrollment. Studies have identified at least four major challenges to achieving a substantial understanding of financial relationships in clinical research. First there is wide variation in views and practice about what to tell participants about a researcher’s financial relationships.

Delays in vaccine trials inject flu questions
Rochester Democrat and Chronicle
“Having the answers sooner rather than later will be better. But it’s understandable that we don’t have them. “Three of the five trials at Rochester Clinical Research in Irondequoit one of 15 testing sites across the country are under way. Another is scheduled to start in September and the last one in ctober. “There will be vaccine” said Patricia Larrabee president and chief executive officer of RCR “but it may not be in the quantity as early as we want it. “Health experts are watching how H1N1 behaves in other parts of the world in order to predict its effect here. “Things may not hit till January” Larrabee said.

- Disclosure of Financial Relationships to Participants in Clinical …
- Duke to begin $700M hospital expansion
- Local medical lab testing H1N1 vaccine
- Getting clinical trials on track

Disclosure of Financial Relationships to Participants in Clinical …
New England Journal of Medicine (subscription)
Potential Goals and Challenges of Disclosing Financial Relationships in Clinical Research. Promoting Informed Decision MakingDisclosures to research participants during the informed-consent process are meant to promote autonomous decision making. 789 What exactly constitutes an autonomous decision by the participant is a matter of debate but most experts describe it as a choice made after the person has gained a substantial understanding of the potential risks and benefits of enrollment. Studies have identified at least four major challenges to achieving a substantial understanding of financial relationships in clinical research. First there is wide variation in views and practice about what to tell participants about a researcher’s financial relationships.

Duke to begin $700M hospital expansion
WRAL.com
"This project is all about our patients faculty and staff and our missions of clinical care teaching and pursuing breakthrough research. "The project also will act as an economic driver for the region creating up to 1500 construction jobs and 1000 permanent health care positions officials said. The seven-story 267000-square-foot cancer center will consolidate outpatient cancer services and clinical research from across the campus into a patient-centered multidisciplinary center. It will adjoin to the Morris Cancer Clinic and will include 140 examination rooms 75 infusion stations a pharmacy and an outdoor garden terrace for chemotherapy patients. "Patients in North Carolina and elsewhere will have access to a center of excellence that combines the best in convenient multidisciplinary cancer care along with leading edge approaches to personalized treatment strategies" Dr. William Fulkerson Jr. senior vice president for clinical affairs for Duke Health said in a statement.

Local medical lab testing H1N1 vaccine
KVBC
For nearly ten years Dr. Steven Folkerth has been working with the Clinical Research Center of Nevada testing the latest drugs and vaccines on valley residents for FDA approval. “A clinical trial occurs when there is either going to be a new medication or vaccine that needs to be studied” he explains of his work. “It's a very controlled process by the FDA. ” In the past the center has been involved in the testing of vaccines for the bird flu Smallpox and even Anthrax.
Related from Mommie-care: More than 1000 volunteer to test swine flu vaccine in King County

Getting clinical trials on track
News & bserver
It may sometimes be that the best trial design from a scientific perspective is also the one least likely to reach its enrollment goals. Any costs that come with the needed change would seem to pale in comparison to the money time and vast potential lost in trials that never reach completion. Billions of dollars many of them federal tax dollars are spent on clinical research each year. The recent federal stimulus package allocated $200 million to clinical research studies to compare the effectiveness of drugs or other medical interventions and give doctors the data they need to provide their patients — all of us — with the best care based on the evidence. So the next time you hear an advertisement on the radio or read a flier at the doctor’s office please take an extra minute or two to consider whether you might be willing and able to help turn those dollars into a real difference.

- Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
- Pleiad Devices Selects mniComm Systems as their eClinical …
- Research and Markets: Clinical Research Manual: International …
- » Clinical Research Associate
- NIAID to ffer $100M for Immune System Research Centers
- Encorium Reports Second Quarter 2009 Financial Results
- CCA Focus: Insulin Resistance in Diabetes and Cardiovascular Disease

Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
PR Newswire (press release)
We operate under the concept of DATATRAK NE(TM) which encompasses our unique single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK’s eClinical((TM)) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International Inc. ’s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies.

Pleiad Devices Selects mniComm Systems as their eClinical …
PR Newswire (press release)
“We are pleased to once again be collaborating with Pleiad as the exposure generated from working closely on a continual basis with such a specialized internationally renowned CR will undoubtedly raise our profile within the international clinical community” commented Stephen Johnson mniComm’s C. “We expect that as we continue to work with well respected high profile organizations such as Pleiad we will continue to attract companies of an equally high caliber to our dramatically enhanced service offering. We feel that we can offer organizations engaged in clinical research a significant advantage over their peers with our highly specialized portfolio of eClinical solutions designed to greatly simplify the clinical process. ” “TrialMaster has been an essential option for us to provide to our customers. Much is made about the importance of subject compliance in clinical research but we find that study coordinator ‘compliance’ is also very critical. The TrialMaster EDC system is very intuitive so the study coordinators with whom we work have little problem in getting their work completed within the allocated time” stated Stephen Brandao Pleiad’s Vice President of Business Development. “We find that mniComm is an attentive partner very much in tune with the needs of our business.

Research and Markets: Clinical Research Manual: International …
Business Wire (press release)
A practical annually updated international handbook for all those working in clinical research. The editors have a wealth of experience between them of the teaching and practice of clinical research and have selected and reviewed each chapter to ensure completeness and relevance.

» Clinical Research Associate
Hays Pharma
00 per annumLocationBulgaria25 Aug 2009ur client a global CR is looking for Clinical Research Associates in Bulgaria. DescriptionThe responsibility of a Clinical Research Associate is to perform the clinical monitoring aspect of designated projects in accordance with my client's SPs. lapadatu@hayspharma.

NIAID to ffer $100M for Immune System Research Centers
GenomeWeb Daily News
These studies will exploit recent scientific advances in systems biology integrating information about an organism’s genes proteins and metabolism with data from the host NIAID said. “The observations made and the new methodologies developed by investigators within this program will assist clinical research in vaccine development and beyond” NIAID’s Director of the Division of Allergy Immunology and Transplantation Daniel Rotrosen said. “These research centers are part of NIAID’s long-range goal to identify the principles of human immune regulation and then apply that knowledge to understanding treating and preventing immune-mediated and infectious diseases. ” Related Stories$4M NIH Grant Supports Synchrotron Work in Protein Structure Proteomics and Life Sciences.

Encorium Reports Second Quarter 2009 Financial Results
PR Newswire (press release)
About Encorium Group Inc. Encorium Group Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical biotechnology and medical device industries. The Company’s mission is to provide its clients with high quality full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise experienced team management and advanced technologies. Encorium believes that its expertise in the design of complex clinical trials its therapeutic experience and commitment to excellence and its application of innovative technologies offer its clients a means to more quickly and cost effectively move products through the clinical development process.

CCA Focus: Insulin Resistance in Diabetes and Cardiovascular Disease
Cardiosource
Suzanne Hughes: I know you have a very strong background as a nurse practitioner in the field of preventive cardiology. For the last several years along with working in a clinical setting you have worked in a research environment studying insulin resistance. How is this work different for you? And what have you learned in studying insulin resistance that is applicable to the field of cardiovascular risk reduction? Cindy Lamendola: Well even in clinical research there is always an opportunity for patient education and now my focus not only includes cardiovascular risk factors and prevention but also insulin resistance prediabetes and the different mechanisms that lead up to cardiovascular disease and type 2 diabetes and other clinical outcomes. The best part of being involved in research is just that—there are so many opportunities to look at mechanisms that influence different clinical outcomes. In the past 12 years of working in research on insulin resistance we have seen the consequences of insulin resistance grow from prediabetes diabetes and cardiovascular risk factors that increase risk for cardiovascular disease to now include: polycystic ovary syndrome nonalcoholic fatty liver disease obstructive sleep apnea and schizophrenia as well as other possible outcomes such as some type of cancers and cardiomyopathy. We now know that when we see patients with these other medical problems they may also be at increased risk for type 2 diabetes and heart disease. 1SH: How exactly is insulin resistance measured?CL: Currently the gold standard is by doing a test called a Euglycemic CLAMP or an insulin sensitivity test.
Related from Medcylopaedia: Type 2 diabetics more susceptible to dementia

- Mother’s Immune System May Block Fetal Treatments for Blood Diseases
- Helix BioPharma Announces the Appointment of Kazimierz Roszkowski …
- Physicians bust myths about Insulin
- DATATRAK International Inc. Announces 2009 Second Quarter and …
- Scientific Research into Dysphagia Treatment Modality Reaches …
- Take care when discussing phase I trial options
- p-Ed Contributor Clinical Trials Wrapped in Red Tape

Mother’s Immune System May Block Fetal Treatments for Blood Diseases
PR Newswire (press release)
In a new study in animals the researchers showed that the mother’s immune response interferes with the offspring’s earlier ability to tolerate transplanted donor cells. The study team concludes that focusing on transplant techniques that avoid the maternal immune response may allow scientists to take advantage of fetal tolerance to achieve a long-sought goal of treating blood diseases prenatally. While cautioning that much work must be done to understand how these animal findings apply to humans the current findings are “surprising but reassuring” said study leader Alan W. of the Children’s Center for Clinical Research at The Children’s Hospital of Philadelphia. The study appeared online August 3 in the Journal of Clinical Investigation.
Related from Indoorenvirons: Superbugs learning to ‘network’ with human immune system: researcher

Helix BioPharma Announces the Appointment of Kazimierz Roszkowski …
PR Newswire (press release) (press release)
com Editor’s Note: Photograph is available on request This News Release contains certain forward-looking statements and information regarding the Company’s product development initiatives and in particular its L-DS47 new drug candidate which statements and information can be identified by the use of forward-looking terminology such as “continue” “drive” “towards” “forward” “guide” “into and through the clinical development process” “developing” or variations thereon or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix’s actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation the Company’s need for additional capital which if not obtained in a timely manner or at all will have a material adverse impact on the Company its research and development programs and ultimately its ability to continue; the impact of the global economic downturn and credit crisis which have negatively affected the availability of additional capital particularly for development stage biotechnology companies such as Helix; uncertainty whether L-DS47 or Topical Interferon Alpha-2b will be successfully developed and commercialized as a drug or at all; the need for additional pre-clinical and clinical research and development which may not be successful or completed in a timely manner; manufacturing and upscaling risks including the possibility that further challenges may arise in connection with the manufacture of clinical batches of L-DS47 or Topical Interferon Alpha-2b which could further delay or otherwise negatively affect the Company’s planned development programs; the risk of obtaining negative findings or factors that may become apparent during the course of research or development which may result in the discontinuation or delay of the research or development projects; the need for future clinical trials the occurrence and success of which cannot be assured; product liability and insurance risks; the risk of technical obsolescence; the need for further regulatory approvals which may not be obtained in a timely matter or at all; intellectual property risks; Helix’s dependence on numerous third parties including without limitation contract research organizations contract manufacturing organizations clinical trial consultants collaborative research consultants regulatory affairs advisors and others whose performance and interdependence can critically affect the Company’s performance and the achievement of its milestones; Helix’s dependence on its licensor of the L-DS47 antibody and on the antibody license granted to Helix for the continued development of L-DS47; the need to secure new strategic relationships which is not assured to commercialize L-DS47 and any other drug candidates which may arise out of DS47; the risk that the Company’s license optionee for Topical Interferon Alpha-2b may not continue to provide the Company with interferon alpha-2b or exercise its option which would have a negative effect on the further development of the drug candidate and on the Company; the risk of unanticipated expenses or unanticipated reductions in revenue or both; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix’s products; and the risk of changes in business strategy or development plans. Such risks and uncertainties and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information are more fully described in the Company’s latest Annual Information Form MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at.

Physicians bust myths about Insulin
24 Medica
Lingvay said is to begin analyzing how the insulin plus metformin and oral triple therapy regimens affect insulin production in beta cells. ther UT Southwestern researchers involved in the study included Jaime Legendre recipient of a Clinical Research Fellowship from the Doris Duke Charitable Foundation; Dr. Polina Kaloyanova former fellow in endocrinology; Dr. Song Zhang assistant professor of clinical sciences; and Beverley Adams Huet assistant professor of clinical sciences. The study was supported by Novo Nordisk Inc. the National Institutes of Health and the Doris Duke Charitable Foundation.

DATATRAK International Inc. Announces 2009 Second Quarter and …
PR Newswire (press release)
Backlog consists of anticipated revenue from authorization letters to commence services statements of work and other signed contracts yet to be completed. Potential contracts or authorization letters that have passed the verbal stage but have not yet been signed are excluded from backlog. The June 30th backlog figure does not reflect the previously announced signing of a letter of intent with a leading global clinical research organizations (CR) for trial services on a Phase III trial awarded to DATATRAK by the European division of a Global Top 20 Pharmaceutical company in July with an estimated backlog amount of $745000. During the quarter the Company’s cash balance declined to $1. 63 million at June 30 2009 compared to $2. 08 million as of March 31 2009. Approximately 47% of the $446000 cash decrease or $208000 is attributable to the payment of severance commitments primarily to former executive officers of the Company.

Scientific Research into Dysphagia Treatment Modality Reaches …
Advertiser Talk
The paper “Neuromuscular Electrical Stimulation in the Treatment of Dysphagia: A Summary of the Evidence” shows that the scientific data has proliferated over the past two years at an unprecedented rate. Neuromuscular Electrical Stimulation (NMES) used as an adjunct modality in the treatment of dysphagia has gained increasing adoption by medical professionals since the clearance by the Food and Drug Administration of VitalStim® Therapy the only device on the market with such clearance. (FDA 2002) According to Yorick Wijting director of clinical research for VitalStim “The need for clinical data to support the efficacy of electrical stimulation in the continuing treatment of dysphagia is being satisfied by independent medical researchers around the world. “Research activity in this area is unparalleled in the history of dysphagia research. Available data now provide substantial scientific and clinical support for the addition of electrotherapy in the treatment of dysphagia to enhance treatment outcomes. In actual fact available evidence supporting the use of NMES for dysphagia at present exceeds the evidence supporting other reimbursable interventions used in the treatment of dysphagia. ” Use of NMES in the treatment of dysphagia involves the administration of small electrical impulses to swallowing muscles in the throat through electrodes attached to the skin overlying the musculature.

Take care when discussing phase I trial options
American Medical News
This topic continues to spark controversy for two important reasons: the frequent exhaustion of the few standard treatment options available for many patients with advanced cancers and several common yet fundamental misconceptions about phase I trials and their goals. Due to the lack of expected benefit to the immediate participant and the trials’ controversial nature an oncologist who decides not to raise the possibility of phase I studies with some patients has not violated professional obligations or ethics. In fact discussing phase I trials with every patient may have unintended negative consequences for some particularly if their decision comes at the expense of more intensive palliation or even a hospice referral. See related content.

p-Ed Contributor Clinical Trials Wrapped in Red Tape
New York Times
Stanford University researchers have estimated that it cost them about $56000 in administrative wages 18 months of delay and 10000 pages of paper to make a small change to an already-approved research program that simply compared the progress made by patients attending different types of addiction-treatment programs. The lengthy approval process cuts into scientific productivity. David Dilts the director of clinical research at the Knight Cancer Institute in regon found that 30 percent of all board-approved oncology trials are eventually abandoned. To circumvent overbearing federal boards researchers occasionally turn to for-profit independent review boards to approve their studies. These boards cost less and work quickly but some have dangerously lax standards. This spring the Government Accountability ffice announced that it had submitted a fabricated study of a fake surgical adhesive gel called Adhesiabloc to an independent review board which approved the protocol by unanimous vote saying the “gel is probably very safe. ” Even if a study gets approval from an institutional review board it’s not clear that the subjects are all that protected.

- p-Ed Contributor Clinical Trials Wrapped in Red Tape
- Insurance reform could improve access to care
- Nicholas Vogelzang MD Joins US ncology Research Network via …
- Chemical shortage hits hospitals research

p-Ed Contributor Clinical Trials Wrapped in Red Tape
New York Times
Stanford University researchers have estimated that it cost them about $56000 in administrative wages 18 months of delay and 10000 pages of paper to make a small change to an already-approved research program that simply compared the progress made by patients attending different types of addiction-treatment programs. The lengthy approval process cuts into scientific productivity. David Dilts the director of clinical research at the Knight Cancer Institute in regon found that 30 percent of all board-approved oncology trials are eventually abandoned. To circumvent overbearing federal boards researchers occasionally turn to for-profit independent review boards to approve their studies. These boards cost less and work quickly but some have dangerously lax standards. This spring the Government Accountability ffice announced that it had submitted a fabricated study of a fake surgical adhesive gel called Adhesiabloc to an independent review board which approved the protocol by unanimous vote saying the “gel is probably very safe. ” Even if a study gets approval from an institutional review board it’s not clear that the subjects are all that protected.

Insurance reform could improve access to care
Houston Chronicle
Insurance companies should not be required to subsidize clinical research; however health plans should provide coverage for routine care for patients enrolled in clinical trials. Routine care coverage is what would be provided to the patient regardless of participation in a trial which 26 states and Medicare already require. Working through the details of a program like this would be healthy for America cost-effective for U. consumers and would reduce the noninsured in this country markedly without expanding Medicare or other government programs.
Related from Fathernickthomas: Health-care reform for kids

Nicholas Vogelzang MD Joins US ncology Research Network via …
PR Newswire (press release)
Vogelzang to the long line of prestigious cancer researchers working in the US ncology Research network” says Steve Smith vice president of US ncology Research. “His talents will allow us to assess clinical trials in a variety of cancers rarely seen in the network in prior years. ” “US ncology Research has developed a strong reputation for doing excellent clinical research on a national level. The addition of Dr. Vogelzang who is well known for his work in GU malignancies and drug development only strengthens our ability to perform at a very high level” says Stephen Jones M. medical director of the US ncology Research network “We are excited about him joining the network.

Chemical shortage hits hospitals research
WHYY
Chaitanya Divgi is chief of nuclear medicine at the University of Pennsylvania. He says research using technetium has decreased this year. Divgi: In clinical research the ability to do bone scans to follow patients’ treatment courses has been impacted. And the ability to do brain scans with technetium has been impacted…Sometimes when protocols have already begun in clinical research and you’re midway through and then you find that one of the tests you’re using for evaluation of your therapeutic agent may not be available it’s a blow. Doctors can use other methods such as cat scans or pet scans to substitute for technetium. But Divgi says developing countries where technetium is the primary diagnostic tool might not be able to make the switch.

- Assistant/Associate Professor
- omnicomm Systems Signs Licensing Deal with West Coast Clinical …
- Science and Pseudoscience in Adult Nutrition Research and Practice
- Firm seeks volunteers for clinical trials
- Post-stroke depression recovery improved by adding brief …
- Threshold Pharmaceuticals Reports Second Quarter 2009 Financial …

Assistant/Associate Professor
Nature.com (subscription)
The successful candidate will have modern laboratory space located in the newly opened Center for Life Science Building. Joint appointments in the Program in Genomics at Children?s Hospital and the Broad Institute of MIT and Harvard may be available for appropriate applicants. The Division resides within a very strong research and clinical community in genetics developmental biology and related disciplines throughout the Harvard Longwood Medical Area and offers many teaching and clinical opportunities. The Clinical Scientist will hold both Children?s Hospital Boston and Harvard Medical School faculty appointments.

omnicomm Systems Signs Licensing Deal with West Coast Clinical …
PR Newswire (press release) (press release)
(TCBulletinBoard: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that it has entered into a licensing agreement with a west coast Clinical Research rganization (CR) for the use of their TrialMaster(TM) solution in a Technology Transfer model. The agreement is expected to generate more than $1. 1 million from licensing maintenance hosting and consulting fees for mniComm over the next three years. It also allows this leading CR to expand its offering to its customers to include the latest in cutting edge technologies for electronic data capture. “We are extremely pleased to have been selected by this new client and we believe that our unique platform of eClinical solutions is being recognized within the clinical research community as a valuable and important tool for facilitating the development of life-saving drugs and devices” said Stephen Johnson mniComm’s C.
Related from Murtoughsupply: Take that West Coast

Science and Pseudoscience in Adult Nutrition Research and Practice
Skeptical Inquirer
Doctors know that clinical research rarely advances in one giant leap; instead it advances incrementally. ”23 The editors did not blame themselves (and other editors) for publishing low-quality or uninterpretable papers. Instead the editors blamed the media which should “improve the way they interpret science. ” Angell and Kassirer then stated that “the public at large needs to become much more sophisticated about clinical research particularly epidemiology” because “what medical journals publish is not received wisdom but rather working papers. ”23Thus they as journal editors placed the burden on the student nutritionist medical scientist physician public and media to determine what is valid important and meaningful sometimes with the help of editorials.

Firm seeks volunteers for clinical trials
East Brunswick Sentinel
(ACCRINC) an independent clinical research site dedicated to full-service care is looking for volunteers for its clinical trials. Trials that are available now are: osteoarthritis and rheumatoid arthritis; migraine; menstrual migraine; osteoporosis; fibromyalgia; and hypertension and flu vaccine according to Melissa Cardillo M.

Post-stroke depression recovery improved by adding brief …
7thSpace Interactive (press release)
Becker professor of neurology; Ann Buzaitis nurse UW Medical Center Neurology Clinic; Kevin C. Cain research scientist Biostatistics; Michael Fruin nurse practitioner and clinical faculty member School of Nursing; David Tirschwell associate professor of neurology; and Linda Teri interim chair and professor of psychosocial and community health and director Northwest Research Group on Aging. The National Institute of Nursing Research a component of the National Institutes of Health funded the research. # # # The University of Washington School of Nursing is consistently the nation’s No. 1-ranked nursing school according to U. News & World Report.

Threshold Pharmaceuticals Reports Second Quarter 2009 Financial …
GlobeNewsWire (press release) (press release)
A webcast presentation of the clinical trial results can be found on the Company’s website. n August 4 TH-302 clinical trial results were presented at the World Congress on Lung Cancer Meeting. The presentation by Dr. Glen Weiss Director of Thoracic ncology at the Virginia G. Piper Cancer Center’s Scottsdale Clinical Research Institute summarized results from two Phase 1 clinical trials of TH-302. The two clinical trials are both evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors; one in combination with other chemotherapy agents and the other with TH-302 as monotherapy. Data from these trials were previously discussed at the ASC Meeting in May 2009.

- A Better Way to Conduct Clinical Research
- mniComm Systems Signs Licensing Deal with West Coast Clinical …
- Clinical research coordinator chef sell 2BD
- Research and Markets: Central and Eastern Europe: utsourcing …
- The Foundation for National Institutes of Health Announces …
- MSU to offer postgraduate course in Pharmacogenomics

A Better Way to Conduct Clinical Research
Drug Discovery & Development
Even seniors are adept at managing their bank accounts online and rarely step inside of banks. Having digital technology at our fingertips gives us instant access to information that once required thumbing through reams of paper and provides the ability to make quick work of laborious and menial tasks. The Past: Clinical research digitization slow to catch onClinical research a process that generates collects and analyzes large amounts of data lends itself naturally to the digitization process. However the adoption of information technology in clinical research has been glacially slow when compared to other industries and the mass adoption of the Internet. Why has it taken so long? I agree with my colleague Dr. Joseph DeVeaugh-Geiss a former international director of central nervous system clinical research at GlaxoSmithKline who feels that part of the reason for slow adoption is mindset. “You have to get through to the generations that you can make a transaction without touching a piece of paper” he said.

mniComm Systems Signs Licensing Deal with West Coast Clinical …
PR Newswire (press release) (press release)
(TCBulletinBoard: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that it has entered into a licensing agreement with a west coast Clinical Research rganization (CR) for the use of their TrialMaster(TM) solution in a Technology Transfer model. The agreement is expected to generate more than $1. 1 million from licensing maintenance hosting and consulting fees for mniComm over the next three years. It also allows this leading CR to expand its offering to its customers to include the latest in cutting edge technologies for electronic data capture. “We are extremely pleased to have been selected by this new client and we believe that our unique platform of eClinical solutions is being recognized within the clinical research community as a valuable and important tool for facilitating the development of life-saving drugs and devices” said Stephen Johnson mniComm’s C.

Clinical research coordinator chef sell 2BD
Blockshopper
She has been the National Lung Screening Trial Coordinator at Georgetown University’s Lombardi Comprehensive Cancer Center. Prior to that she was a clinical research assistant at the university.

Research and Markets: Central and Eastern Europe: utsourcing …
Business Wire (press release) (press release)
researchandmarkets. The number of clinical trials initiated in Central and Eastern Europe more than tripled from 2002 to 2007 making the region a key part of global clinical research. This comprehensive analysis focuses on the evolution of the clinical trials industry in the CEE region and the outsourcing strategies that CRs and emerging pharmaceutical and biotech companies need to operate there. Topics include: Market information on 25+ countries including: Bulgaria Czech Republic Hungary Poland Romania Russia Turkey and Ukraine EU directives and other European regulatory trends Exclusive interviews with executives from the top CRs Factors driving growth Companies acquiring local CRs and why Current drug development pipeline riginal and proprietary charts and graphs Central and Eastern Europe is recommended for: Biotech and pharmaceutical companies seeking information on growth and challenges in the Central and Eastern Europe market Investment firms covering the life sciences industry in emerging markets CRs conducting business in Central and Eastern European countries Don’t miss out on this important resource detailing the growing clinical trials industry in Central and Eastern Europe! For more information visit.

The Foundation for National Institutes of Health Announces …
PR Newswire (press release) (press release)
chairman of the Foundation for NIH. “We are grateful to sanofi-aventis for advancing NIH-sponsored clinical research with this generous donation and hope that other pharmaceutical companies will follow its lead. ” “We are proud to support the ability of the NIH to pursue new and cutting-edge research by freeing up much needed resources” said Marc Cluzel M. Senior Vice President Research & Development at sanofi-aventis. “We have been committed to supporting clinical research in key therapeutic areas for more than 50 years and this partnership is another example of the company’s steadfast commitment to advancing research and ultimately helping patients.
Related from Vguideu: We Need More Renaissance Scientists

MSU to offer postgraduate course in Pharmacogenomics
Indian Express
init(”tabnavhc2″ 0) M S UNIVERSITY (MSU) has decided to introduce a post-graduate degree course in Pharmacogenomics from the next academic year. Pharmacogenomics is a new branch of pharmacology that studies the influence of genetic variation on drug response on patients. MSU has received the seed money from the Centre under the 11th Five-Year Plan to start the course in Pharmacogenomics and Clinical Research. MSU ViceChancellor Prof Ramesh Goyal told Newsline : “MSU has mooted proposals to start courses in Pharmacogenomics and clinical research under the 11th Five Year Plan. These courses will be open pharmacy students as well as graduates in pure science. There is an Indian Council for Medical Research (ICMR) centre in Pondicherry that is doing research in the field of Pharmacogenomics. “He added: “But there are not many centres and institutes in the country that offer courses in Pharmacogenomics.

- Neurotez Inc. Awarded Multi-Million Dollar NIH Grant to Advance a …
- Growing Midwestern Clinical Research rganization Selects mniComm …
- Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
- Blacksburg’s Intrexon: Branching out in biotech

Neurotez Inc. Awarded Multi-Million Dollar NIH Grant to Advance a …
Business Wire (press release)
“The entire Neurotez team is very excited to move our drug forward to the next level. This award shows that translational research – when conducted methodically and by the right people – can be executed most effectively in the environment and culture fostered in small biotech companies” said Nikolaos Tezapsidis founder president & CE of Neurotez Inc. We also strongly believe that this award will effectively serve as a bridge to private capital raises. ” “Leptin treatment has shown striking results in numerous cellular and animal models of AD and reduces all of the major pathological hallmarks associated with the disease and as such markedly improves memory. This award presents a wonderful opportunity to move our impressive preclinical studies into clinical trials in patients” said Mark A.
Related from Fildak: China pledges multi-million-dollar aid to Senegal

Growing Midwestern Clinical Research rganization Selects mniComm …
PR Newswire (press release)
(TCBulletinBoard: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research rganization (CR) has selected mniComm to provide eClinical solutions in connection with two of the CR’s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. “We are pleased to have been selected by this CR to provide eClinical solutions for these important Phase IV studies” said Cornelis F. Wit mniComm’s President and CE.

Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
Business Wire (press release)
Shames Assistant Professor of Surgery Division of Transplant Surgery at the Medical College of Wisconsin “Development of a non-invasive test that could help differentiate between acute renal injury rejection and infection would satisfy a critical unmet need in transplantation. A biomarker test that can accomplish this would be of extreme importance in pre-clinical kidney transplantation research. ” Jim Janicki Vice President and General Manager of Life Technologies’ Transplantation Diagnostics Business “The launch of the PlexMark assay represents the continued expansion of our pre-clinical research business. We are excited about the non-invasive and cost-effective nature of PlexMark and anticipate that research clinicians will want to utilize this product to better understand immunosuppression as it relates to whole kidney function. ” Resources.

Blacksburg’s Intrexon: Branching out in biotech
Roanoke Times
Cory Donovan who directs the NewVa Corridor Technology Council said Intrexon stands out in the high-tech business world locally for several things. It is relatively large as council members and research center tenants go and is one of a small number of NewVa region firms to receive investments from Third Security LLC a Radford venture capital firm. Sunil Chada Intrexon’s senior vice president of clinical research and development said in a news release the firm is “very encouraged” by recent events. Rob Patzig chief investment officer at Third Security said the melanoma therapy is “on track to significantly enhance the safety and efficacy of cancer treatments while also maintaining centralized production and distribution efficiencies. John Kirkwood the physician leading the study could not be reached for comment.

- Blacksburg’s Intrexon: Branching out in biotech
- Growing Midwestern Clinical Research rganization Selects mniComm …
- Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
- VICC earns accreditation for human research subjects protection
- Are wind farms a health risk? US scientist identifies ‘wind …

Blacksburg’s Intrexon: Branching out in biotech
Roanoke Times
Cory Donovan who directs the NewVa Corridor Technology Council said Intrexon stands out in the high-tech business world locally for several things. It is relatively large as council members and research center tenants go and is one of a small number of NewVa region firms to receive investments from Third Security LLC a Radford venture capital firm. Sunil Chada Intrexon’s senior vice president of clinical research and development said in a news release the firm is “very encouraged” by recent events. Rob Patzig chief investment officer at Third Security said the melanoma therapy is “on track to significantly enhance the safety and efficacy of cancer treatments while also maintaining centralized production and distribution efficiencies. John Kirkwood the physician leading the study could not be reached for comment.

Growing Midwestern Clinical Research rganization Selects mniComm …
PR Newswire (press release)
(TCBulletinBoard: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research rganization (CR) has selected mniComm to provide eClinical solutions in connection with two of the CR’s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. “We are pleased to have been selected by this CR to provide eClinical solutions for these important Phase IV studies” said Cornelis F. Wit mniComm’s President and CE.

Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
Business Wire (press release)
Shames Assistant Professor of Surgery Division of Transplant Surgery at the Medical College of Wisconsin “Development of a non-invasive test that could help differentiate between acute renal injury rejection and infection would satisfy a critical unmet need in transplantation. A biomarker test that can accomplish this would be of extreme importance in pre-clinical kidney transplantation research. ” Jim Janicki Vice President and General Manager of Life Technologies’ Transplantation Diagnostics Business “The launch of the PlexMark assay represents the continued expansion of our pre-clinical research business. We are excited about the non-invasive and cost-effective nature of PlexMark and anticipate that research clinicians will want to utilize this product to better understand immunosuppression as it relates to whole kidney function. ” Resources.

VICC earns accreditation for human research subjects protection
Vanderbilt University News
The goal is to ensure that all participants are respected and protected from unnecessary harm. To earn accreditation organizations must provide tangible evidence of their adherence to scientifically and ethically sound research. Accreditation is the gold standard for research organizations to demonstrate this ethical behavior and to build confidence among patients in the quality of clinical research. js’>©2009 Vanderbilt Medical CenterEditorial tool created by Vanderbilt Medical Center Web DevelopmentSEARCH THE REPRTER.

Are wind farms a health risk? US scientist identifies ‘wind …
Independent
They cause problems ranging from internal pulsation quivering nervousness fear a compulsion to flee chest tightness and tachycardia – increased heart rate. Turbine noise can also trigger nightmares and other disorders in children as well as harm cognitive development in the young she claims. However Dr Pierpont also makes it clear that not all people living close to turbines are susceptible. Until now the Government and the wind companies have denied any health risks associated with the powerful noises and vibrations emitted by wind turbines. Acoustic engineers working for the wind energy companies and the Government say that aerodynamic noise produced by turbines pose no risk to health a view endorsed recently by acousticians at Salford University. They have argued that earlier claims by Dr Pierpont are “imaginary” and are likely to argue that her latest findings are based on a sample too small to be authoritative.
Related from Golf-monster: Australians Day Jones lead Puerto Rico pen

- VICC earns accreditation for human research subjects protection
- Growing Midwestern Clinical Research rganization Selects mniComm …
- Clinical trials set for vaccine for H1N1 virus
- Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …

VICC earns accreditation for human research subjects protection
Vanderbilt University News
The goal is to ensure that all participants are respected and protected from unnecessary harm. To earn accreditation organizations must provide tangible evidence of their adherence to scientifically and ethically sound research. Accreditation is the gold standard for research organizations to demonstrate this ethical behavior and to build confidence among patients in the quality of clinical research. js’>©2009 Vanderbilt Medical CenterEditorial tool created by Vanderbilt Medical Center Web DevelopmentSEARCH THE REPRTER.

Growing Midwestern Clinical Research rganization Selects mniComm …
PR Newswire (press release) (press release)
(TCBulletinBoard: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research rganization (CR) has selected mniComm to provide eClinical solutions in connection with two of the CR’s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. “We are pleased to have been selected by this CR to provide eClinical solutions for these important Phase IV studies” said Cornelis F. Wit mniComm’s President and CE.

Clinical trials set for vaccine for H1N1 virus
Middletown Journal
Prestige Clinical Research at 333 Conover Drive Suite D is set to begin human trials mid-month said Dr. Gary Bedel principal investigator for Prestige. He said the center would be enrolling candidates for the trial through mid-September. Bedel said there are two primary groups that will be targeted at the Franklin center: children ages 3 to 9 and adults 65 and older. “We are trying to get as many people involved as possible” Bedel said.
Related from Cghyjx: Hualan Biological starts A/H1N1 vaccine R & D

Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
Business Wire (press release)
Shames Assistant Professor of Surgery Division of Transplant Surgery at the Medical College of Wisconsin “Development of a non-invasive test that could help differentiate between acute renal injury rejection and infection would satisfy a critical unmet need in transplantation. A biomarker test that can accomplish this would be of extreme importance in pre-clinical kidney transplantation research. ” Jim Janicki Vice President and General Manager of Life Technologies’ Transplantation Diagnostics Business “The launch of the PlexMark assay represents the continued expansion of our pre-clinical research business. We are excited about the non-invasive and cost-effective nature of PlexMark and anticipate that research clinicians will want to utilize this product to better understand immunosuppression as it relates to whole kidney function. ” Resources.